| Ytd | -16.51% | |
| 1y | -21.41% |
| Open | 196.99 | Prev Close | 194.88 | Low | 197.89 | High | 203.22 | Mkt Cap | 29.17B |
| Vol | 875.27K | Avg Vol | 1.42M | EPS | 10.38 | P/E | 19.37 | Forward P/E | 16.10 |
| Beta | 0.78 | Short Ratio | 8.56 | Inst. Own | 70.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 05-14 | Earning | 08-06 | 50-d Avg | 201.95 | 200-d Avg | 239.44 | 1yr Est | 260.60 |
RMD News
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While th
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans t
ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpen
Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the pri
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J
Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in compani